Company intelligence / Profile preview

Hollenbeck Pharmaceuticals

Falls Village, Connecticut, United Stateshollenbeckpharma.com ↗

Ownership: Private
Development stage: Other

Overview

HOL-101, an orphan-designated diagnostic for growth hormone deficiency (GHD) in adults and children, is the current lead. Clinical results not yet publicly available. Company expected trials to start in 2021, but as of 2024/2025, status implies early/initial clinical development; no published clinical efficacy data found

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Hollenbeck Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hollenbeck Pharmaceuticals.

Explore the full profile